Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 4
1993 2
1995 1
1996 4
1997 5
1998 3
1999 2
2000 3
2001 1
2002 1
2003 2
2005 1
2006 1
2007 2
2008 3
2009 2
2011 1
2012 1
2013 3
2015 2
2016 4
2017 1
2018 3
2019 6
2020 3
2021 5
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

63 results
Results by year
Filters applied: . Clear all
Page 1
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Hillig RC, Sautier B, Schroeder J, Moosmayer D, Hilpmann A, Stegmann CM, Werbeck ND, Briem H, Boemer U, Weiske J, Badock V, Mastouri J, Petersen K, Siemeister G, Kahmann JD, Wegener D, Böhnke N, Eis K, Graham K, Wortmann L, von Nussbaum F, Bader B. Hillig RC, et al. Among authors: siemeister g. Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2551-2560. doi: 10.1073/pnas.1812963116. Epub 2019 Jan 25. Proc Natl Acad Sci U S A. 2019. PMID: 30683722 Free PMC article.
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Wengner AM, Siemeister G, Lücking U, Lefranc J, Wortmann L, Lienau P, Bader B, Bömer U, Moosmayer D, Eberspächer U, Golfier S, Schatz CA, Baumgart SJ, Haendler B, Lejeune P, Schlicker A, von Nussbaum F, Brands M, Ziegelbauer K, Mumberg D. Wengner AM, et al. Among authors: siemeister g. Mol Cancer Ther. 2020 Jan;19(1):26-38. doi: 10.1158/1535-7163.MCT-19-0019. Epub 2019 Oct 3. Mol Cancer Ther. 2020. PMID: 31582533 Free article.
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer.
Dieter SM, Siegl C, Codó PL, Huerta M, Ostermann-Parucha AL, Schulz E, Zowada MK, Martin S, Laaber K, Nowrouzi A, Blatter M, Kreth S, Westermann F, Benner A, Uhrig U, Putzker K, Lewis J, Haegebarth A, Mumberg D, Holton SJ, Weiske J, Toepper LM, Scheib U, Siemeister G, Ball CR, Kuster B, Stoehr G, Hahne H, Johannes S, Lange M, Herbst F, Glimm H. Dieter SM, et al. Among authors: siemeister g. Cell Rep. 2021 Jul 20;36(3):109394. doi: 10.1016/j.celrep.2021.109394. Cell Rep. 2021. PMID: 34289372 Free article.
Molecular biology of insulin resistance.
Müller-Wieland D, Streicher R, Siemeister G, Krone W. Müller-Wieland D, et al. Among authors: siemeister g. Exp Clin Endocrinol. 1993;101(1):17-29. doi: 10.1055/s-0029-1211203. Exp Clin Endocrinol. 1993. PMID: 8477820 Review.
Radiobiological effects of the alpha emitter Ra-223 on tumor cells.
Bannik K, Madas B, Jarzombek M, Sutter A, Siemeister G, Mumberg D, Zitzmann-Kolbe S. Bannik K, et al. Among authors: siemeister g. Sci Rep. 2019 Dec 6;9(1):18489. doi: 10.1038/s41598-019-54884-7. Sci Rep. 2019. PMID: 31811257 Free PMC article.
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
Lücking U, Kosemund D, Böhnke N, Lienau P, Siemeister G, Denner K, Bohlmann R, Briem H, Terebesi I, Bömer U, Schäfer M, Ince S, Mumberg D, Scholz A, Izumi R, Hwang S, von Nussbaum F. Lücking U, et al. Among authors: siemeister g. J Med Chem. 2021 Aug 12;64(15):11651-11674. doi: 10.1021/acs.jmedchem.1c01000. Epub 2021 Jul 15. J Med Chem. 2021. PMID: 34264057
63 results